Quote:There is no one on staff with a medical degree.
Quite a bit of jackassery, look at the lineup.
Scott Hansen, PhD
Head of Research & Basic Science
Dr. Hansen has 25 years of experience in the field of virology and immunology, 17 of which were focused on the development and utilization of the non-human primate (NHP) model for the study of host vs. pathogen interactions, disease state modeling, and vaccine development.
Scott Hansen, PhD
Head of Research & Basic Science
Dr. Hansen has 25 years of experience in the field of virology and immunology, 17 of which were focused on the development and utilization of the non-human primate (NHP) model for the study of host vs. pathogen interactions, disease state modeling, and vaccine development. He is currently an Associate Professor at OHSU, where he has earned recognition for his strong publication record.
Bernie Cunningham, PhD, MRPharmS, PMP
Vice President of Operations
Dr. Cunningham, a certified Project Management Professional with extensive experience in development of investigational medicinal products (IMP) including solid oral dosage forms, cell therapies, radiopharmaceuticals and monoclonal antibodies
Joseph Meidling
Senior Director of Clinical Operations
Mr. Meidling joined CytoDyn in March of 2021 as Senior Director of Portfolio and Project Management and in May of 2022 was appointed Senior Director of Clinical Operations. Prior to joining CytoDyn, Mr. Meidling spent nearly 22 years at Merck where he held various positions of increasing responsibilities in Drug Development. He was a director in Clinical Pharmacology and Translational Medicine and led the Pharmacogenomics and Biorepository group before moving on to become the site lead for Merck’s Kenilworth facility and was responsible for Merck’s Early-Stage Development portfolio and resource planning. Mr. Meidling
non-staff
Stephen M. Simes
Director
Mr. Simes is an accomplished public company CEO who led a number of biopharmaceutical companies during his over 40 year career in the industry. He has extensive experience developing and implementing corporate strategies, establishing growth metrics, driving performance, and meeting growth objectives through organic expansion, acquisitions, and partnerships. When CEO at RestorGenex Corporation, Mr. Simes built a successful senior executive leadership team that delivered significant therapeutic products and stockholder value. He also negotiated the merger of RestorGenex with Diffusion Pharmaceuticals (NASDAQ: DFFN), creating a late-stage oncology-focused biotech company. As CEO at BioSante Pharmaceuticals, Inc., Mr. Simes helped secure significant funding through various financing transactions, acquisitions, and license arrangements.
Ryan Dunlap
Director
Mr. Dunlap has over 25 years’ experience in finance and operations leadership, developing significant expertise in strategy setting, improving operational efficiency and effectiveness, fundraising and investor relations, financial reporting and compliance, and risk management.
Karen J. Brunke, PhD
Director
Dr. Brunke has over 30 years of scientific, operational, clinical, senior executive, and corporate development managerial experience with large and small biotechnology companies.
Lishomwa C. Ndhlovu, MD, PhD
Director
Appointed to Weill Cornell Medicine in 2019 as Professor of Immunology in Medicine and Neuroscience, Dr. Ndhlovu has served on the Company’s Scientific Advisory Board since July 2020. Before joining Weill Cornell Medicine, Dr. Ndhlovu was a Professor at the University of Hawaii from 2011 to 2019, where he retains an adjunct appointment. As Co-leader of the $26.5 million NIH—Martin Delaney Collaboratory for HIV Cure “HOPE.”, he is a recognized expert in basic and complex immunology and immunotherapy research. He has focused much of his work on confronting the challenges of HIV and aging, addressing molecular mechanism of HIV and COVID-19 pathogenesis, complications and persistence.
16
